The sigma-I (σ1) receptor and its role in the treatment of mood disorders

Drugs of the Future

Volumn 34, Issue 2, 2009, Pages 137-146

  Hayashi, T ^a   Stahl, S M ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHAPERONE; DEXTROMETHORPHAN; DONEPEZIL; FLUVOXAMINE; HALOPERIDOL; HYPERFORIN; HYPERICIN; IMIPRAMINE; MEMBRANE PROTEIN; OPIPRAMOL; PENTAZOCINE; PRASTERONE SULFATE; PREGNENOLONE SULFATE; PROGESTERONE; SERTRALINE; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR;

CALCIUM SIGNALING; CELL SURVIVAL; DRUG RECEPTOR BINDING; ENDOPLASMIC RETICULUM; MOOD DISORDER; MYELINATION; REVIEW; SYNAPTOGENESIS;

EID: 74049102232     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.02.1336115     Document Type: Review

References (90)

1. Stahl, S.M. Stahl's Essential Psychopharmacology, 3rd Ed. Cambridge University Press: New York, 2008.
2. Pittenger, C, Duman, R.S. Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology 2008, 33(1): 88-109.
3. Sahay, A., Hen, R. Hippocampal neurogenesis and depression. Novartis Found Symp 2008, 289:152-60; discussion 160-4,193-5.
4. Gould, T.D., Picchini, A.M., Einat, H., Manji, H.K. Targeting glycogen synthase kinase-3 in the CNS: Implications for the development of new treatments for mood disorders. Curr Drug Targets 2006,7(11): 1399-409.
5. Liu, X.Y., Yang, J.L., Chen, LJ. et al. Comparative proteomics and correlated signaling network of rat hippocampus in the pilocarpine model of temporal lobe epilepsy. Proteomics 2008, 8(3): 582-603.
6. Hisaoka, K., Takebayashi, M., Tsuchioka, M., Maeda, N., Nakata, Y., Yamawaki, S. Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther 2007, 321(1): 148-57.
7. Takebayashi, M., Hayashi, X, Su, XP. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: Implications for antidepressants. J Pharmacol Exp Ther 2002, 303(3): 1227-37.
8. Walker, J.M., Bowen, W.D., Walker, F.O., Matsumoto, R.R., De Costa, B., Rice, KC Sigma receptors: Biology and function. Pharmacol Rev 1990, 42(4): 355-402.
9. Hayashi, T, Su, XP. An update on the development of drugs for neuropsychiatrie disorders: Focusing on the sigma 1 receptor ligand. Expert Opin Ther Targets 2008,12(1): 45-58.
10. Bowen, W.D., Hellewell, S.B., McGarry, K.A. Evidence for a multi-site model of the rat brain sigma receptor. Eur J Pharmacol 1989,163(2-3): 309-18.
11. Maurice, T Neurosteroids and sigmal receptors, biochemical and behavioral relevance. Pharmacopsychiatry 2004,37(Suppl. 3): S171-82.
12. Su, T.P. Evidence for sigma opioid receptor: Binding of [3HJSKF-10047 to etorphine-inaccessible sites In guinea-pig brain. J Pharmacol Exp Ther 1982,223(2): 284-90.
13. Hanner, M., Moebius, F.F., Flandorfer, A. et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sei USA 1996,93(15): 8072-7.
14. Hayashi, T, Su, T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007,131(3): 596-610.
15. Hayashi, T, Su, T.P. Sigma-1 receptors (slgma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: Roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther 2003, 306(2): 718-25.
16. Hayashi, T, Su, T.P. Intracellular dynamics of sigma-1 receptors (sigma(1) binding sites) in NG108-15 cells. J Pharmacol Exp Ther 2003, 306(2): 726-33.
17. Kitaichi, K., Chabot, JC, Moebius, F.F., Flandorfer, A., Glossmann, H., Quirion, R. Expression of the purported sigma(1) (sigma(1)) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy. J Chem Neuroanat 2000,20(3-4): 375-87.
18. Aydar, E., Palmer, CP, Djamgoz, M.B. Sigma receptors and cancer: Possible involvement of ion channels. Cancer Res 2004, 64(15): 5029-35.
19. Satpati, D., Bapat, K., Sarma, H.D., Kothari, K., Venkatesh, M., Banerjee, S. Synthesis of 99mTc-nitrido heterocomplex of piperidine and in vitro and in vivo evaluation of its affinity for sigma receptors. Cancer Biother Radiopharm 2008, 23(1): 34-42.
20. Alonso, G, Phan, V, Guillemain, I, Saunier, M., Legrand, A., Anoal, M., Maurice, T. Immunocytochemical localization of the sigma(l) receptor in the adult rat central nervous system. Neuroscience 2000,97(1): 155-70.
21. Matsumoto, R.R, Hemstreet, M.K., Lai, N.L. et al. Drug specificity of pharmacological dystonia. Pharmacol Biochem Behav 1990,36(1): 151-5.
22. Hayashi, T, Su, T The sigma receptor: Evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol 2005,3(4): 267-80.
23. Schroder, M., Kaufman, R.J. ER stress and the unfolded protein response. Mutat Res 2005, 569(1-2): 29-63.
24. Kopito, R.R., Ron, D. Conformational disease. Nat Cell Biol 2000, 2(11): E207-9.
25. Ng, F, Berk, M, Dean, O., Bush, A.I. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008,11(6): 851-76.
26. Kakiuchi, C, Ishiwata, M., Nanko, S. et al. Functional polymorphisms of HSPA5: Possible association with bipolar disorder. Biochem Biophys Res Commun 2005,336(4): 1136-43.
27. Bown, C, Wang, J. F, MacQueen, G, Young, L.T. Increased temporal cortex ER stress proteins in depressed subjects who died by suicide. Neuropsychopharmacology 2000, 22(3): 327-32.
28. Solit, D.B, Rosen, N. Hsp90: A novel target for cancer therapy. Curr Top Med Chem 2006, 6(11): 1205-14.
29. Hajnoczky, C, Hoek, J.B. Cell signaling. Mitochondrial longevity pathways. Science 2007,315(5812): 607-9.
30. Rizzuto, R, Pozzan, T. Microdomains of intracellular Ca2+: Molecular determinants and functional consequences. Physiol Rev 2006,86(1): 369-408.
31. Duchen, M.R, Verkhratsky, A., Muallem, S. Mitochondria and calcium in health and disease. Cell Calcium 2008, 44(1): 1-5.
32. Bermack, J, Lavoie, N, Dryver, E, Debonnel, G. Effects of sigma ligands on NMDA receptor function in the bulbectomy model of depression: A behavioural study in the rat. lnt J Neuropsychopharmacol 2002, 5(1): 53-62.
33. Nuwayhid, S.J., Werling, L.L. Sigmal receptor agonist-mediated regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release is dependent upon protein kinase C. J Pharmacol Exp Ther 2003,304(1): 364-9.
34. Hayashi, T, Su, T.P. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: Implication for drug abuse. Life Sci 2005, 77(14): 1612-24.
35. Yagasaki, Y., Numakawa, T., Kumamaru, E., Hayashi, T, Su, XP, Kunugi, H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J Biol Chem 2006, 281(18): 12941-9.
36. Hayashi, T., Su, T.P. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci USA 2004,101(41): 14949-54.
37. Tsai, S.Y., Hayashi, T., Su, T.P. Hippocampal dendritogenesis and associated anchoring of NMDA and AMPA receptors are controlled by sigma-1 receptors. Int J Neuropsychopharmacol 2006,9(Suppl. 1): S167.
38. Zhang, H, Cuevas, J. Sigma receptors inhibit high-voltage-activated calcium channels in rat sympathetic and parasympathetic neurons. J Neurophysiol 2002, 87(6): 2867-79.
39. Renaudo, A., L'Hoste, S., Guizouarn, H., Borgese, F., Soriani, O. Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl- channels. J Biol Chem 2007, 282(4): 2259-67.
40. Aydar, E., Palmer, C.P., Klyachko, V.A., Jackson, M.B. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002, 34(3): 399-410.
41. Katnik, C., Guerrero, W.R., Pennypacker, K.R., Herrera, Y., Cuevas, J. Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. J Pharmacol Exp Ther 2006, 319(3): 1355-65.
42. Hayashi, T., Su, T.P. Sigma-1 receptor ligands: Potential in the treatment of neuropsychiatrie disorders. CNS Drugs 2004,18(5): 269-84.
43. Hashimoto, K., Ishiwata, K. Sigma receptor ligands: Possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006, 12(30): 3857-76.
44. Stahl, S.M. The sigma enigma: Can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 2008, 69(11): 1673-74.
45. Narita, N, Hashimoto, K, Tomitaka, S, Minabe, Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996, 307(1): 117-9.
46. Nishimura, T., lshima, T., lyo, M., Hashimoto, K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: Role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS ONE 2008, 3(7): e2558.
47. Hashimoto, K., Fujita, Y., lyo, M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxam ine: Role of sigma-1 receptors. Neuropsychopharmacology 2007, 32(3): 514-21.
48. Ishikawa, M., Ishiwata, K, lshii, K. et at. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: A positron emission tomography study using [11CJSA4503. Biol Psychiatry 2007, 62(8): 878-83.
49. Yamamoto, H, Miura, R, Yamamoto, T. et al. Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding. FEBS Lett 1999,445(1): 19-22.
50. Pal, A, Chu, UB, Ramachandran, S, Grawoig, D, Guo, L.W., Hajipour, A.R., Ruoho, A.E. Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the sigma-1 receptor. J Biol Chem 2008, 283(28): 19646-56.
51. Chen, Y, Hajipour, A.R, Sievert, M.K, Arbabian, M, Ruoho, A.E. Characterization of the cocaine binding site on the sigma-1 receptor. Biochemistry 2007,46(11): 3532-42.
52. Schläger, T., Schepmann, D, Würthwein, E.U, Wünsch, B. Synthesis and structure-affinity relationships of novel spirocyclic sigma receptor ligands with furopyrazole structure. Bioorg Med Chem 2008,16(6): 2992-3001.
53. Nahas, R.I., Lever, J.R., Lever, S.Z. Synthesis and structure-activity relationships of N-(3-phenylpropyl)-N′-benzylpiperazines: Potent ligands for sigmal and sigma2 receptors. Bioorg Med Chem 2008,16(2): 755-61.
54. Akunne, H.C., Whetzel, S.Z., Wiley, J.N. et al. The pharmacology of the novel and selective sigma ligand, PD 144418. Neuropharmacology 1997, 36(1): 51-62.
55. Glennon, R.A., Ablordeppey, S.Y., lsmaiel, A.M., el-Ashmawy, M.B., Fischer, J.B., Howie, K.B. Structural features important for sigma 1 receptor binding. J Med Chem 1994, 37(8): 1214-9.
56. Matsumoto, R.R., Liu, Y., Lerner, M., Howard, E.W., Brackett, D.J. Sigma receptors: Potential medications development target for anti-cocaine agents. Eur J Pharmacol 2003,469(1-3): 1-12.
57. Snyder, S.H., Largent, B.L. Receptor mechanisms in antipsychotic drug action: Focus on sigma receptors. J Neuropsychiatry Clin Neurosci 1989, 1(1): 7-15.
58. Ferris, CD, Hirsch, D.J., Brooks, B.P., Snyder, S.H. Sigma receptors: From molecule to man. J Neurochem 1991, 57(3): 729-37.
59. Okuyama, S., Imagawa, Y., Sakagawa, T. et al. NE-100, a novel sigma receptor ligand: Effect on phencyclidine-induced behaviors in rots, dogs and monkeys. Life Sci 1994, 55(7): PL133-8.
60. Matsuno, K., Kobayashi, T., Tanaka, M.K., Mita, S. Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol 1996,312(3): 267-71.
61. Matsumoto, R.R, Shaikh, J, Wilson, LL, Vedam, S, Coop, A. Attenuation of methamphetamine-induced effects through the antagonism of sigma (sigma) receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol 2008,18(12): 871-81.
62. Urani, A, Roman, RJ, Phan, VL, Su, TP, Maurice, X The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001,298(3): 1269-79.
63. Tottori, K., Miwa, T., Uwahodo, Y. et al. Antidepressant-Hke responses to the combined sigma and 5-HTIA receptor agonist OPC-14523. Neuropharmacology 2001, 41(8): 976-88.
64. Bermack, J.E., Debonnel, G. The role of sigma receptors in depression. J Pharmacol Sei 2005, 97(3): 317-36.
65. Bermack, J.E., Debonnel, G Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br J Pharmacol 2001,134(3): 691-9.
66. Su, T.P., Hayashi, T. Understanding the molecular mechanism of sigma-1 receptors: Towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003,10(20): 2073-80.
67. Bermack, J.E., Debonnel, G. Effects of OPC-14523, a combined sigma and 5-HTIa ligand, on pre- and postsynaptic 5-HTIa receptors. J Psychopharmacol 2007, 21(1): 85-92.
68. Espallergues, J, Lapalud, P., Christopoulos, A., Avlani, V.A., Sexton, P.M., Vamvakides, A., Maurice, T. Involvement of the sigmal (sigmal) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahy-drofuran derivative ANAVEXI-41. Br J Pharmacol 2007,152(2): 267-79.
69. Langa, F, Codony, X., Tovar, V et al. Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. Eur J Neurosci 2003, 18(8): 2188-96.
70. Johannessen, M., Fontanilla, D., Hajipour, A.R., Pal, A., Cozzi, N.V., Jackson, M.B., Ruoho, A.E. N,N-Dimethyitryptamine (DMT) as an endogenous ligand candidate for the sigma-1 receptor. 38th Annu Meet Soc Neurosci (Nov 15-19, Washington, DC) 2008, Abst 660.10.
71. Sabino, V., Cottone, P., Parylak, S. L., Steardo, L., Zorrilla, E.P. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res 2009,198(2): 472-6.
72. Takebayashi, M, Hayashi, T., Su, T.P. A perspective on the new mechanism of antidepressants: Neuritogenesis through sigma-1 receptors. Pharmacopsychiatry 2004,37(Suppl. 3): S208-13.
73. Dhir, A, Kulkarni, S.K. Involvement of sigma ({sigma}1) receptors in modulating the anti-depressant effect of neurosteroids (dehydroepiandrosterone or pregnenolone) in mouse toil-suspension test. J Psychopharmacol 2008, 22(6): 691-6.
74. Dubrovsky, B. Neurosteroids, neuroactive steroids, and symptoms of affective disorders. Pharmacol Biochem Behav 2006,84(4): 644-55.
75. Uzunova, V, Sheline, Y, Davis, J.M, Rasmusson, A., Uzunov, D.P., Costa, E, Guidotti, A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sei USA 1998,95(6): 3239-44.
76. Pinna, G., Costa, E., Guidotti, A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl) 2006, 186(3): 362-72.
77. Dubrovsky, B.O. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 2005,29(2): 169-92.
78. Borison, R.L., Diamond, B.I, Dren, A.T. Does sigma receptor antagonism predict clinical antipsychotic efficacy? Psychopharmacol Bull 1991, 27(2): 103-6.
79. Müller, M.J., Gründer, G., Wetzel, H., Müller-Siecheneder, F., Marx-Dannigkeit, P, Benkert, O. Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: An open clinical trial. Psychiatry Res 1999,89(3): 275-80.
80. Gewirtz, G.R., Gorman, J.M., Volavka, J., Macaluso, J., Gribkoff, G., Taylor, D.P., Borison, R. BMY14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 1994,10(1): 37-40
81. Modell, S, Naber, D., Holzbach, R. Efficacy and safety of an opiate sigmareceptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: An open dose-range study. Pharmacopsychiatry 1996, 29(2): 63-6.
82. Volz, H.P, Stoll, K.D. Clinical trials with sigma ligands. Pharmacopsychiatry 2004,37(Suppl. 3): S214-20.
83. Gatti, F, Bellini, L, Gasperini, M, Perez, J, Zanardi, R., Smeraldi, E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996,153(3): 414-6.
84. Stahl, S.M. Antidepressant treatment of psychotic major depression: Potential role of the sigma receptor. CNS Spectr 2005,10(4): 319-23.
85. Serretti, A, Lattuada, E, Zanardi, R, Franchini, L, Smeraldi, E. Patterns of symptom improvement during antidepressant treatment of delusional depression. Psychiatry Res 2000,94(2): 185-90.
86. Silver, H. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 2004, 5(10): 2053-8.
87. Pande, AC, Geneve, J, Scherrer, B. Igmesine, a novel sigma ligand, has antidepressant properties. 21st Congr Coll lnt Neuro-Psychopharmacol (July 12-16, Glasgow) 1998, Abst SM0505.
88. Matsuno, K., Nakazawa, M., Okamoto, K., Kawashima, Y., Mita, S. Binding properties ofSA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol 1996,306(1-3): 271-9.
89. Li, Z., Cui, S., Zhang, Z., Zhou, R., Ge, Y., Sokabe, M., Chen, L. DHEA-neu-roprotection and -neurotoxicity after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 2009, 29(2): 287-96.
90. Ajmo, C.T Jr., Vernon, D.O., Collier, L, Pennypacker, K.R., Cuevas, J. Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats. Curr Neurovasc Res 2006,3(2): 89-98.